DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28687340Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18158338 | https://www.ncbi.nlm.nih.gov/pubmed/28271418 | https://www.ncbi.nlm.nih.gov/pubmed/16380540 | https://www.ncbi.nlm.nih.gov/pubmed/18677709
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28687340
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18158338 | https://www.ncbi.nlm.nih.gov/pubmed/28271418 | https://www.ncbi.nlm.nih.gov/pubmed/16380540 | https://www.ncbi.nlm.nih.gov/pubmed/18677709
Angiotensin III (Ang III) is a bioactive heptapeptide that is formed from the degradation of the Angiotensin II peptide by aminopeptidase A. In peripheral Angiotensin systems, Angiotensin II is the main effector peptide in the systemic circulation, although exogenous Angiotensin III can be as potent as Angiotensin II in, for example, stimulating aldosterone secretion or inhibiting renin release. In the rat brain, Angiotensin III was found to be equipotent with Angiotensin II as a pressor agent or dipsogen and was bound as avidly to the nervous system as Angiotensin II. Angiotensin receptor subtype AT1 has the greater affinity towards Angiotensin II and is also responsive to Angiotensin III, while the AT2 receptor subtype appears to be more sensitive to Angiotensin III but less responsive to Angiotensin II. Angiotensin III enhances blood pressure, vasopressin release and thirst when it is centrally administrated. Angiotensin III infusion increases blood pressure in healthy volunteers and hypertensive patients as well as augments aldosterone release. Although Angiotensin III does not change renal function in humans, it induces natriuresis in AT, receptor-blocked rats likely by binding to AT2 receptors. In addition, in cultured renal cells, this peptide stimulates the expression of many growth factors, proinflammatory mediators, and extracellular matrix proteins.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL227 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8515427 |
5.57 nM [IC50] | ||
Target ID: CHEMBL4607 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8515427 |
1.74 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
The renin angiotensin system--its physiology and role in disease states. | 1983 Nov |
|
The neuronal role of angiotensin II in thirst, sodium appetite, cognition and memory. | 1996 Nov |
|
[Renal effects of AT1 angiotensin receptor antagonists (AT1ra)]. | 1997 Dec 20 |
|
Important role for angiotensin III and IV in the brain renin-angiotensin system. | 1997 Sep 30 |
|
[Active metabolites derived from angiotensin II]. | 1998 |
|
Bioactive angiotensin peptides. | 1998 May |
|
[Angiotensin I, angiotensin II, angiotensin III]. | 1999 Dec |
|
Role of the renin-angiotensin system in vascular diseases: expanding the field. | 2001 Dec 1 |
|
Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. | 2002 Dec |
|
Organisation and functional role of the brain angiotensin system. | 2002 Sep |
|
New bioactive angiotensins formation pathways and functional involvements. | 2004 |
|
Dietary fat and hypertension: a novel approach through the proteolytic regulatory enzymes of the renin-angiotensin-system. | 2006 Jul |
|
Brain aminopeptidases and hypertension. | 2006 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16380540
Ang III (3.5, 7, and 14 nmol/kg per minute) was infused cumulatively into the renal interstitialspace of the left (experimental) kidney each rat after a 1-hour control infusion
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18677709
Human prostate cancer cell (DU145 and LNCaP) were used for activity evaluation. LNCaP and DU145 cells were seeded onto 24-well plates at a density of 2–5x10^4 cells/well. Cells were treated with Ang-III at various concentrations as indicated in the figures for 5 days. Simultaneously, the cells were pretreated with olmesartan for 30 min, and cultured in phenol red-freeRPMI plus 0.1% BSA in the presence of Ang-III for 5 days. After incubation in 5% CO2 at 37C, cells were harvested with trypsin and cell numbers were determined with a cell counter on day 5.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
72941629
Created by
admin on Sat Dec 16 09:28:38 GMT 2023 , Edited by admin on Sat Dec 16 09:28:38 GMT 2023
|
PRIMARY | |||
|
1354552-78-5
Created by
admin on Sat Dec 16 09:28:38 GMT 2023 , Edited by admin on Sat Dec 16 09:28:38 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
2AY78S427U
Created by
admin on Sat Dec 16 09:28:38 GMT 2023 , Edited by admin on Sat Dec 16 09:28:38 GMT 2023
|
PRIMARY | |||
|
100900-06-9
Created by
admin on Sat Dec 16 09:28:38 GMT 2023 , Edited by admin on Sat Dec 16 09:28:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD